Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: A case report with literature review

Seren Durer, Ceren Durer, Madeeha Shafqat, Isin Yagmur Comba, Saad Malik, Warda Faridi, Shehroz Aslam, Awais Ijaz, Muhammad Junaid Tariq, Muhammad Asad Fraz, Muhammad Usman, Ali Y. Khan, Ali McBride, Faiz Anwer

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations

Abstract

Blinatumomab and donor lymphocyte infusion (DLI) combination is a promising cancer therapy, whereby blinatumomab might achieve an initial reduction in leukemic-cell burden using T cells, and after tumor clearance, DLI can potentially stimulate the donor immune system to achieve longer lasting remission. Here, we present a 51-year-old female with mixed phenotype acute leukemia who had a hematologic relapse 3 months after she received total body irradiation-based myeloablative allogeneic hematopoietic stem cell transplantation from an unrelated human leukocyte antigen matched (10/10) donor and achieved complete remission with minimal residual disease negativity by multi-parameter flow cytometry using the combination of blinatumomab and DLI. To the best of our knowledge, this is the first report to describe the use of blinatumomab and DLI combination therapy in the treatment of B/myeloid mixed phenotype acute leukemia.

Original languageEnglish (US)
Pages (from-to)373-378
Number of pages6
JournalImmunotherapy
Volume11
Issue number5
DOIs
StatePublished - Apr 2019

Keywords

  • B/myeloid subtype
  • CD19
  • MPAL
  • acute leukemia
  • biphenotypic leukemia
  • bispecific T-cell engager
  • blinatumomab
  • donor lymphocyte infusion
  • immunotherapy
  • mixed-phenotype acute leukemia

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint

Dive into the research topics of 'Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: A case report with literature review'. Together they form a unique fingerprint.

Cite this